Background & Aims: Gluten challenge is used to diagnose celiac disease (CeD) and for clinical research. Sustained gluten exposure reliably induces histologic changes but is burdensome. We investigated the relative abilities of multiple biomarkers to assess disease activity induced by 2 gluten doses, and aimed to identify biomarkers to supplement or replace histology.
Methods: In this randomized, double-blind, 2-dose gluten-challenge trial conducted in 2 US centers (Boston, MA), 14 adults with biopsy-proven CeD were randomized to 3 g or 10 g gluten/d for 14 days. The study was powered to detect changes in villous height to crypt depth, and stopped at planned interim analysis on reaching this end point. Additional end points included gluten-specific cluster of differentiation (CD)4 T-cell analysis with HLA-DQ2-gluten tetramers and enzyme-linked immune absorbent spot, gut-homing CD8 T cells, interleukin-2, symptoms, video capsule endoscopy, intraepithelial leukocytes, and tissue multiplex immunofluorescence.
Results: All assessments showed changes with gluten challenge. However, time to maximal change, change magnitude, and gluten dose-response relationship varied. Villous height to crypt depth, video capsule endoscopy enteropathy score, enzyme-linked immune absorbent spot, gut-homing CD8 T cells, intraepithelial leukocyte counts, and HLA-DQ2-restricted gluten-specific CD4 T cells showed significant changes from baseline at 10 g gluten only; symptoms were significant at 3 g. Symptoms and plasma interleukin-2 levels increased significantly or near significantly at both doses. Interleukin-2 appeared to be the earliest, most sensitive marker of acute gluten exposure.
Conclusions: Modern biomarkers are sensitive and responsive to gluten exposure, potentially allowing less invasive, lower-dose, shorter-duration gluten ingestion. This work provides a preliminary framework for rational design of gluten challenge for CeD research. ClinicalTrials.gov number, NCT03409796.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878429 | PMC |
| http://dx.doi.org/10.1053/j.gastro.2020.10.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Living with Pediatric Coeliac Disease: Lessons for Health Service Delivery.
Dig Dis Sci
January 2025
Department of Paediatric Gastroenterology, Hepatology and Liver Transplant, Queensland Children's Hospital, Graham St, South Brisbane, 4101, Australia.
Background: Coeliac Disease (CD) affects up to 1.4% of children worldwide, with a rising global incidence. A less typical clinical presentation and the need for a life-long gluten exclusion diet raise challenges for diagnosis, management, and healthcare delivery with considerable impacts for CD patients and families as well as clinical services.
View Article and Find Full Text PDFGenomic loci associated with grain protein and mineral nutrients concentrations in under contrasting water regimes.
Front Plant Sci
December 2024
R. H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel.
Climate change is becoming a global challenge, threating agriculture's capacity to meet the food and nutritional requirements of the growing population. Underutilized crops present an opportunity to address climate change and nutritional deficiencies. Tef is a stress-resilient cereal crop, producing gluten-free grain of high nutritional quality.
View Article and Find Full Text PDFImpact of a Gluten-Free Diet in Adults With Celiac Disease: Nutritional Deficiencies and Challenges.
Cureus
December 2024
Department of Internal Medicine, Taibah University, Al-Madinah, SAU.
Celiac disease (CD) is a long-term inflammatory condition affecting the small intestines, characterized by bowel villi atrophy and mucosal histological alterations that lead to impaired nutrient absorption and metabolic changes. While a gluten-free diet (GFD) is recognized as one of the most effective treatments, it presents significant challenges including increased expenses, potential nutritional deficiencies, and various social and psychological implications. This review evaluates the comprehensive impact of GFD on CD patients, examining its efficacy in preventing complications like osteoporosis and alleviating symptoms, while also addressing the difficulties in maintaining complete gluten elimination.
View Article and Find Full Text PDFA randomized, double-blind, placebo-controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease.
Clin Transl Sci
January 2025
F. Hoffmann-La Roche, Basel, Switzerland.
Celiac disease is a chronic, immune-mediated enteropathy with symptoms triggered by exposure to dietary gluten in genetically predisposed individuals. The only available management option is lifelong adherence to a gluten-free diet. This randomized, double-blind, placebo-controlled, parallel-group, single-center study tested the effects of the cathepsin S inhibitor RO5459072 on the immune response to a 13-day gluten challenge in 19 participants with celiac disease (ClinicalTrials.
View Article and Find Full Text PDFViral infections in celiac disease: what should be considered for better management.
Clin Exp Med
December 2024
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Following a gluten-free diet (GFD) is known as the main effective therapy available for celiac disease (CD) patients, which in some cases is not enough to heal all patients presentations completely. Accordingly, emerging researchers have focused on finding novel therapeutic/preventive strategies for this disorder. Moreover, previous studies have shown that celiac patients, especially untreated subjects, are at increased risk of developing viral and bacterial infections, which can become a challenge for the clinician.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!